Creative Bio-Peptides, Inc. has been awarded over $6M in funding from three NIH agencies. Two grants are each multi-million-dollar awards over a 2-year period as part of the NIH’s HEAL Initiative to provide safe non-opioid pain treatments for the 50 million Americans living with daily chronic pain as well as 2 million Americans who suffer from an opioid use disorder. We have also received NIH funding for Alzheimer’s treatments. The awards come from the Small Business Innovation Research program which supports commercialization of promising treatments. All of these conditions may be improved by our chemokine blocking Receptides®.
The two HEAL awards are from the National Institute of Neurological Disorders and Stroke and the National Institute on Drug Abuse, to complete pre-clinical studies and file a New Drug Application (NDA) for our lead Receptide, RAP-103 to initiate first-in-human safety testing. In the NINDS program we will focus on uses in pain, in the NIDA program new treatments for opioid use disorders.
The National Institute on Aging has recently made a second award to Creative Bio-Peptides for the optimization of a chemokine receptor antagonist peptide as a synapse protecting treatment for neurodegeneration in Alzheimer’s Disease. Our approach seeks to reverse early synapse loss to improve memory and cognition in this and other dementias.